Taking HPDA, which provided favorable biocompatibility and low cytotoxicity, as a carrier, H-APBC was developed for as an anti-cancer therapeutic agent in breast cancer, while also modifying the HIF-1-dependent tumor hypoxia adaptation. This evidence concerns the gene HIF1A and breast carcinoma.